Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Anixa Biosciences stock

Learn how to easily invest in Anixa Biosciences stock.

Anixa Biosciences Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 4 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Anixa Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANIX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Anixa Biosciences stock price (NASDAQ: ANIX)

Use our graph to track the performance of ANIX stocks over time.

Anixa Biosciences shares at a glance

Information last updated 2022-01-17.
Latest market close$3.10
52-week range$2.71 - $8.09
50-day moving average $3.60
200-day moving average $4.21
Wall St. target price$11.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.45

Buy Anixa Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Anixa Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anixa Biosciences price performance over time

Historical closes compared with the close of $3.1 from 2022-01-21

1 week (2022-01-14) -9.09%
1 month (2021-12-23) -2.52%
3 months (2021-10-22) -28.57%
6 months (2021-07-23) -27.06%
1 year (2021-01-22) -26.37%
2 years (2020-01-24) -19.69%
3 years (2019-01-24) 4.94
5 years (2017-01-24) 4.85

Anixa Biosciences financials

Revenue TTM $512,500
Gross profit TTM $127,498
Return on assets TTM -35.92%
Return on equity TTM -61.02%
Profit margin 0%
Book value $1.18
Market capitalisation $102.8 million

TTM: trailing 12 months

Anixa Biosciences share dividends

We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.

Have Anixa Biosciences's shares ever split?

Anixa Biosciences's shares were split on a 1:25 basis on 25 June 2015. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anixa Biosciences shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Anixa Biosciences shares which in turn could have impacted Anixa Biosciences's share price.

Anixa Biosciences share price volatility

Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $2.71 up to $8.09. A popular way to gauge a stock's volatility is its "beta".

ANIX.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.6685. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Anixa Biosciences overview

Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc.

Frequently asked questions

What percentage of Anixa Biosciences is owned by insiders or institutions?
Currently 4.981% of Anixa Biosciences shares are held by insiders and 10.523% by institutions.
How many people work for Anixa Biosciences?
Latest data suggests 4 work at Anixa Biosciences.
When does the fiscal year end for Anixa Biosciences?
Anixa Biosciences's fiscal year ends in October.
Where is Anixa Biosciences based?
Anixa Biosciences's address is: 3150 Almaden Expressway, San Jose, CA, United States, 95118
What is Anixa Biosciences's ISIN number?
Anixa Biosciences's international securities identification number is: US03528H1095
What is Anixa Biosciences's CUSIP number?
Anixa Biosciences's Committee on Uniform Securities Identification Procedures number is: 03528H109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site